RIPK1 and ovarian carcinoma: Zhang et al. reported that ceramide nanoliposomes targeted MLKL activation independently of the RIPK1/RIPK3-regulated pathway in ovarian cancer, and MLKL played a critical role in ceramide nanoliposome-induced necroptosis [30].